Trials / Completed
CompletedNCT02814409
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,858 (actual)
- Sponsor
- NHS Greater Glasgow and Clyde · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin Scale distribution at day 90?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase | IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion |
| DRUG | Intravenous Tenecteplase | IV Tenecteplase 0.25mg/kg (max 25mg) single bolus |
Timeline
- Start date
- 2016-12-15
- Primary completion
- 2023-08-31
- Completion
- 2024-01-10
- First posted
- 2016-06-27
- Last updated
- 2024-06-13
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02814409. Inclusion in this directory is not an endorsement.